Lake Bleu Capital

BangBang Robotics is a service provider of intelligent assistive devices dedicated to creating a new ecology for elderly care, assisting the disabled, and creating a better lifestyle for handicapped groups through technology. Telemedicine, home rehabilitation, and live auxiliary will be integrated to lead the development of assistive device 3.0 through the energization of intelligent technologies. The company owns a number of core independent intellectual property rights as well as approximately 100 patents. The Company's main product lines are home rehabilitation series, traveling auxiliary series, and nursing and physiotherapy series. In China, the company operates more than 100 experiential service stations.

Shenji Bio focuses on the research and development of fundamental raw materials such as nucleosides, nucleotides, diagnostic antigens, and antibodies. As a development direction, Shenji Bio provides cost-effective products and addresses clinical unmet needs. It has gradually entered the upstream core raw material fields of IVD, mRNA, CGT, and other industries, and has established a high-quality key common technology platform to provide overall solutions for the life science field's development.

Tongxin makes magnetically-suspended artificial blood pumps which are designed to replace the human heart. They are undergoing clinical trials in China after being fast-tracked through the approval process by the National Medical Products Administration, state-run Xinhua News Agency

GenFleet Therapeutics is a developer and researcher of molecular pharmaceuticals targeting cancer treatments. The company specializes in developing innovative molecular-level pharmaceuticals and antibody drugs targeting various cancer systems, providing effective medical solutions to reactivate tumor-specific immune responses and to mobilize the body's own immune system.

Duoning Biotech is a serum-free medium and technology developer based on international animal cell culture concepts and process development experience. It is committed to the development and production of serum-free media for new animal cells, while providing formula production and technical support for the biopharmaceutical industry. With ancillary services, the products include basic media such as S1, S2, S3, S3-CD and S4, as well as 2×103 feeds and other feed media based on 2×103 feeds; and customized services.

Singleron Biotechnologies is a developer and provider of clinical diagnosis, health management and drug development products and services. The company is dedicated to applying single cell analysis techniques and has obtained a world wide exclusive IP license from Yale University for its uniquely designed microfluidic single cell processing device, and has developed the innovative SCOPE single-cell pre-sequencing preparation system based on this microfluidic device.

Vision X is a solutions provider for medical equipment in the field of ophthalmology and optometry.

Biocytogen is a biopharmaceutical company that provides biomedical communities with integrated solutions for antibody drug development. Biocytogen developed a seamlessly integrated platform for efficient antibody drug discovery and validation, including animal model generation, therapeutic antibody discovery (via RenMabTM Mouse), and in vivo/in vitro preclinical validation studies, using gene editing technologies and a state-of-the-art animal facility. Biocytogen works with the world's leading pharmaceutical and biotechnology companies.

Valgen focus on treatment technologies and systemic solutions for heart disease, especially for mitral and tricuspid valve lesions.

Developer of digital angiography machines intended to be used in the clinical fields of radiology and cardiology.

AffaMed Therapeutics is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products.

Brii Biosciences is a developer of bio-pharmaceutical medicines intended to provide medical solutions to Chinese patients to fulfill their health and treatment needs. The company's medicines focuses on infectious disease drug development and commercialization in China and leverage technology and data to drive improvements to the Chinese healthcare system and outcomes for patients, enabling patients to get access to better treatments and cures for life-threatening diseases.

Exegenesis is going to develop new medicine based on gene therapy and focuses on China and the global market. The team consists of experienced professionals, including gene therapy drug design, preclinical studies and clinical development.

Abbisko Therapeutics is a drug company dedicated to innovative drug research and development. The company is founded by a group of seasoned drug hunters with rich research and managerial experience in top pharmaceutical companies globally and in China.

Broncus Technologies is a medical technology company focused on developing minimally-invasive medical devices for emphysema and other lung diseases. Broncus is investigating the Exhale emphysema product line to perform our patented treatment method called Airway Bypass. Airway Bypass could be the first minimally-invasive procedure for the treatment of homogeneous, or diffuse, emphysema, which constitutes the majority of the emphysema patient population. Broncus is currently enrolling patients worldwide in our pivotal EASE Trial investigating a treatment of severe homogeneous emphysema. Broncus is located in Mountain View, CA (San Francisco Bay area). Broncus International is located in Nyon, Switzerland.

Ruipeng Pet Hospital is a Shenzhen-based pet medical and beauty care hospital operator, which covers pet healthcare, foster care, bathing, SPA, beauty, food, entertainment and leisure services.

I-MAB is a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. .

Shanghai MicroPort CardioFlow Medtech Co., Ltd. (MicroPort CardioFlow), founded 2015 in the Shanghai Zhangjiang Hi-Tech Park, is a subsidiary of MicroPort Scientific Corporation MicroPort CardioFlow is dedicated to providing advanced minimally invasive therapies for structural heart diseases with its best-in-class capacities in R&D, manufacturing, marketing, and technical consulting services. We believe in “Focus, Innovation, and Globalization”, and in accordance, we place the utmost importance on saving and improving quality of life for patients. Consequently, we constantly strive to bring the most innovative valvular disease treatment solutions to patients while also operating on a global vision to provide all patients and physicians with world-leading products that are superior, reliable, yet affordable.

Beijing Mabworks Biotech, a gene engineering mAb company. Mabworks is working on ZMapp, an Ebola treatment developed by San Diego's MAPP Biopharma. It also is developing two clinical stage drug candidates: MIL60, a biosimilar to Genentech's Avastin, and MIL62, a proposed treatment for chronic lymphocytic leukemia.

RemeGen, Ltd. ("RemeGen") is a biopharmaceutical company in China dedicated to fulfilling unmet medical needs for patients with life-threatening conditions. RemeGen's main focus is research and development, manufacturing and commercialization of novel biologics, most notably monoclonal antibodies (mAb) and antibody-drug conjugates (ADCs). Headquartered in Yantai, Shandong Province, China, RemeGen has labs/offices in Beijing and California.

Rongchang Pharmaceutical has grown into a modern pharmaceutical company enterprise integrating the r$d,production and sales of modern chinese medicine and biological drugs.

The company has built a global level of bio-pharmaceutical research and development and industrialization platform; established for cancer, autoimmune diseases, inflammation and cardiovascular disease of the rich product line. The scale of the company's platform, hardware and software facilities, the number of new drug product lines, R & D team in the country are the same industry-leading level. Kang Fang biological has been with the international and domestic listed pharmaceutical companies to establish a cooperative relationship, the joint development of innovative antibodies to new drugs, is a strategic cooperation in the form of development of new drugs in the forerunner.